24
Participants
Start Date
November 30, 2010
Primary Completion Date
June 30, 2012
Study Completion Date
June 30, 2012
PDC31
This study involves the sequential administration of PDC31 to 4 cohorts of patients. The dose will be escalated in the absence of dose-limiting toxicities. PDC31 is to be administered as a 3-hour continuous infusion.
Innsbruck Medical University, Innsbruck
Medical University of Vienna, Vienna
University Hospital Hamburg-Eppendorf, Hamburg
University of Mainz, Mainz
Lead Sponsor
PDC Biotech GmbH
INDUSTRY